Five-year contract extension with Illumina

Yourgene Health PLC

26 July 2023

 

Yourgene Health plc

("Yourgene", the "Group" or the "Company")

Five-year contract extension with Illumina

Manchester, UK - 26 July 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that it has signed a five-year contract extension with Illumina Inc. ("Illumina"). The contract is a restated licence and supply agreement for Yourgene's sequencing based NIPT IVD products, which will now run until September 2028.

The restated licence provides seamless continuity for existing customers and allows Yourgene to continue its product development roadmaps for NIPT and other future applications in the field of precision medicine, as the Company looks to further penetrate key international markets such as Americas, UK, Europe and Australia.

Lyn Rees, Chief Executive Officer of Yourgene, commented: "We are delighted to continue our partnership with Illumina following a successful five years of working together to date. This provides us with a good opportunity to further develop exciting market opportunities in NIPT across many key markets."

The Directors of the Company take responsibility for this announcement.

Yourgene Health plc Lyn Rees, Chief Executive Officer	Tel: [phone] [e-mail]
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD)	Tel: [phone]
Liam Murray / Ludovico Lazzaretti
Singer Capital Markets (Corporate Broker)	Tel: [phone]
Aubrey Powell / Tom Salvesen / George Tzimas
Walbrook PR Ltd (Media and Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings / Lianne Applegarth	Mob: [phone]

About Yourgene Health

Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.

Building on our expertise in genomic technology, Yourgene's Ranger® Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger® Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.

Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei (divestment pending), Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN".

For more information visit https://yourgenehealth.com/ and follow us on twitter @Yourgene_Health.

 

END